Health- and vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis

British Journal of Ophthalmology

Volumn 97, Issue 3, 2013, Pages 338-342

  Sakai, Tsutomu ^a   Watanabe, Hiroka ^a   Kuroyanagi, Kana ^a   Akiyama, Goichi ^a   Okano, Kiichiro ^a   Kohno, Hideo ^a   Tsuneoka, Hiroshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VISION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84874657522     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302515     Document Type: Article

References (19)

1. Behçet H. Über rezidivierende aphthose, durch ein Virus verusache Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937;105:1152-7.
2. Onal S, Savar F, Akman M, et al. Vision-and health-related quality of life in patients with Behçet uveitis. Arch Ophthalmol 2010;128:1265-71.
3. Süllü Y, Oge I, Erkan D, et al. Cyclosporin-A therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand 1998;76:96-9.
4. Fujino Y, Joko S, Masuda K, et al. Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease. Jpn J Ophthalmol 1999;43:318-26.
5. Tanaka H, Sugita S, Yamada Y, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease. Nippon Ganka Gakkai Zasshi 2010;114:87-95.
6. Okada AA, Goto H, Ohno S, et al., for the Ocular Behcet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet Disease. Arch Ophthalmol 2012;130:592-8.
7. Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Clin Exp Rheumatol 2011;29:S58-63.
8. Behçet's Disease Research Committee of Japan. Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol 1974;18:291-4.
9. Mizushima Y. Recent research into Behçet's disease in Japan. Int J Tissue React 1988;10:59-65.
10. Bhataka BB, Brennan P, James TE, et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999;38:728-33.
11. Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11:341-53.
12. Sakamaki H, Ikeda S, Ikegami N, et al. Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health 2006;9:47-53.
13. Walters SJ, Brazier JE. Comparison of minimally important differences for two health utility measures: EQ-5D and SF-6D. Qual Life Outcomes 2005;14:1523-32.
14. Pickard AS, Neary MP, Cella D. Estimation of minimally important difference in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70.
15. Frick KD, Drye LT, Kempen JH, et al., Multicenter Uveitis Steroid Treatment-MUST Trial Research Group. Associations among visual acuity and vision-and health-related quality of life among patients in the multicenter uveitis steroid treatment trial. Invest Ophthalmol Vis Sci 2012;53:1169-76.
16. Suzukamoto Y, Oshika T, Yuzawa M, et al. Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version. Health Qual Life Outcomes 2005;3:65.
17. Suner IH, Kokame GT, Yu E, et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation Studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 2009;50:3629-55.
18. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patient with Behçet's disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9.
19. Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125:895-900.